专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

US20080182866A1 Tetra-Cyclic Carboline Derivatives Useful in the Inhibition of Angiogenesis 有权
标题翻译：用于抑制血管发生的四环类衍生物
公开(公告)号：US20080182866A1
公开(公告)日：2008-07-31
申请号：US10592761
申请日：2005-03-15
申请人： Young-Choon Moon , Liangxian Cao , Nadarajan Tamilarasu , Hongyan Qi , Soongyu Choi , William Joseph Lennox , Donald Thomas Corson
发明人： Young-Choon Moon , Liangxian Cao , Nadarajan Tamilarasu , Hongyan Qi , Soongyu Choi , William Joseph Lennox , Donald Thomas Corson
IPC分类号： A61K31/437 , A61P43/00
CPC分类号： A61K31/4166 , C07D221/18 , C07D235/02 , C07D239/26 , C07D241/04 , C07D265/30 , C07D307/78 , C07D317/48
摘要： In accordance with the present invention, tetracyclic caboline derivatives that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, these compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy or exudative macular degeneration are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the inhibition of angiogenesis, and/or the treatment of cancer, diabetic retinopathy or exudative macular degeneration using the compounds of the invention.
摘要翻译：根据本发明，已经鉴定了抑制VEGF转录后表达的四环caboline衍生物，并提供了它们的使用方法。在本发明的一个方面，提供了可用于抑制VEGF生成，抑制血管发生和/或治疗癌症，糖尿病性视网膜病变或渗出性黄斑变性的这些化合物。在本发明的另一方面，提供了使用本发明化合物抑制VEGF产生，抑制血管发生和/或治疗癌症，糖尿病性视网膜病变或渗出性黄斑变性的方法。

62. 发明申请

US20080118774A1 Organic electroluminescent materials and organic electroluminescent device using the same 有权
标题翻译：有机电致发光材料和使用其的有机电致发光器件
公开(公告)号：US20080118774A1
公开(公告)日：2008-05-22
申请号：US11602214
申请日：2006-11-21
申请人： Hsiang-Lun Hsu
发明人： Hsiang-Lun Hsu
IPC分类号： B32B9/00 , C07D235/02
CPC分类号： C07D235/02 , Y10S428/917
摘要： An organic electroluminescent material and an organic electroluminescent material used for electroluminescent devices is characterized by emission with a high luminance, high illuminant efficiency, low drive voltage, favorable color purity and high thermal steadiness. The hydrogen atom, halogen atom, cyanide group, alkyl group, alkylidene group, cycloalkane group, alkoxy group, amnio group, aromatic hydroxy group, aromatic bi-alkyl group, alkylaryl group as a substitutive group are used. Not only may it increase the material's glass transition temperature and inhibit the phenomenon of molecular split but also cause this organic electroluminescent device to show a high level of steadiness.
摘要翻译：用于电致发光器件的有机电致发光材料和有机电致发光材料的特征在于具有高亮度，高发光效率，低驱动电压，良好的色纯度和高热稳定性的发射。使用氢原子，卤原子，氰基，烷基，亚烷基，环烷烃基，烷氧基，氨基，芳香族羟基，芳香族双烷基，烷基芳基作为取代基。它不仅可以增加材料的玻璃化转变温度并抑制分子分裂现象，而且还使得该有机电致发光器件显示出高水平的稳定性。

63. 发明申请

US20080103138A1 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions 审中-公开
标题翻译： β-激动剂，其制备方法及其作为药物组合物的用途
公开(公告)号：US20080103138A1
公开(公告)日：2008-05-01
申请号：US11960306
申请日：2007-12-19
申请人： Thomas Trieselmann , Rainer Walter , Matthew Netherton , Marco Santagostino , Bradford Hamilton
发明人： Thomas Trieselmann , Rainer Walter , Matthew Netherton , Marco Santagostino , Bradford Hamilton
IPC分类号： A61K31/5377 , C07D235/06 , A61K31/4184 , A61P3/04 , A61P3/10 , C07D413/12
CPC分类号： C07D235/02 , C07D235/06 , C07D235/26
摘要： The present invention relates to new beta-agonists of general formula (I) wherein the groups R1 to R4 have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers, solvates, hydrates, mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, methods of preparing these compounds and their use as pharmaceutical compositions.
摘要翻译：本发明涉及通式（I）的新的β-激动剂，其中基团R 1至R 4具有权利要求和说明书中给出的含义，互变异构体，其外消旋物，对映异构体，非对映异构体，溶剂合物，水合物，其混合物，其前药及其盐，特别是其与无机或有机酸或碱的生理上可接受的盐，制备这些化合物的方法及其作为药物组合物的用途。

64. 发明申请

US20070252140A1 Heterocyclic Radical or Diradical, the Dimers, Oligomers, Polymers, Dispiro Compounds and Polycycles Thereof, the Use Thereof, Organic Semiconductive Material and Electronic or Optoelectronic Component 有权
标题翻译：杂环自由基或双基，二聚体，低聚物，聚合物，脱胶化合物和多环体，其使用，有机半导体材料和电子或光电子部件
公开(公告)号：US20070252140A1
公开(公告)日：2007-11-01
申请号：US11688777
申请日：2007-03-20
申请人： Michael Limmert , Olaf Zeika , Martin Ammann , Horst Hartmann , Ansgar Werner
发明人： Michael Limmert , Olaf Zeika , Martin Ammann , Horst Hartmann , Ansgar Werner
IPC分类号： H01L51/00 , C07D207/00 , C07D209/56 , C07D221/00 , C07D239/00 , C07D241/00 , C07D245/00 , C07D307/00 , C07D333/00
CPC分类号： H01L51/0051 , C07D235/02 , C08G61/00 , H01L51/002 , H01L51/0067 , H01L51/0071 , H01L51/0081 , H01L51/5076 , Y02E10/549
摘要： The present invention relates to heterocyclic radicals or diradicals, the dimers, oligomers, polymers, dispiro compounds and polycycles thereof, to the use thereof to organic semiconductive materials and to electronic and optoelectronic components.
摘要翻译：本发明涉及其用于有机半导体材料和电子和光电子组分的杂环基团或双基，其二聚体，低聚物，聚合物，二氢化合物和多环体。

65. 发明授权

US07282515B2 Derivatives of azaspiro compounds for the treatment of pain 失效
标题翻译： azaspiro化合物的衍生物用于治疗疼痛
公开(公告)号：US07282515B2
公开(公告)日：2007-10-16
申请号：US10935794
申请日：2004-09-07
申请人： Claus Meese , Norma Selve , Dirk Schmidt
发明人： Claus Meese , Norma Selve , Dirk Schmidt
IPC分类号： A61K31/4166 , A61K31/421 , A61K31/426
CPC分类号： C07D235/02 , A61K31/4164 , A61K31/4166 , A61K31/4184 , A61K31/421 , A61K31/423 , A61K31/424 , A61K31/43 , C07D263/52
摘要： This invention relates to azaspiro compounds and their use as medications especially for the treatment of chronic, chronic-phlogistic and/or neuropathic pain. Compounds that lend themselves particularly well to the production of analgesics include 1,3-diazaspiro[4.5]decane-2,4-dion and 1,3-diazaspiro[4.5]decane-2,4-dithion.
摘要翻译：本发明涉及azaspiro化合物及其用作药物，特别是用于治疗慢性，慢性咽炎和/或神经性疼痛。特别适合镇痛药生产的化合物包括1,3-二氮杂螺[4.5]癸烷-2,4-二酮和1,3-二氮杂螺[4.5]癸烷-2,4-二硫代。

66. 发明授权

US07271270B2 High affinity small molecule C5a receptor modulators 失效
公开(公告)号：US07271270B2
公开(公告)日：2007-09-18
申请号：US10853731
申请日：2004-05-24
申请人： Andrew Thurkauf , Xiao-shu He , He Zhao
发明人： Andrew Thurkauf , Xiao-shu He , He Zhao
IPC分类号： C07D235/02 , C07D233/00
CPC分类号： C07D207/327 , C07C233/11 , C07C233/22 , C07C233/65 , C07C233/66 , C07C233/73 , C07C233/78 , C07C235/46 , C07C235/48 , C07C235/54 , C07C235/60 , C07C235/62 , C07C235/66 , C07C237/20 , C07C323/62 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07C2603/18 , C07D213/38 , C07D213/82 , C07D215/12 , C07D217/04 , C07D217/06 , C07D217/14 , C07D217/16 , C07D231/12 , C07D233/64 , C07D233/68 , C07D235/02 , C07D235/14 , C07D235/18 , C07D317/58 , C07D333/24 , C07D333/28 , C07D333/54 , C07D401/06 , C07D401/12 , C07D403/12 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D471/04
摘要： This invention relates to low molecular weight, non-peptidic, non-peptidomimetic, organic molecules that act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also to such ligands that act as antagonists or inverse agonists of complement C5a receptors. Preferred compounds of the invention possess some or all of the following properties in that they are: 1) multi-aryl in structure, 2) heteroaryl in structure, 3) a pharmaceutically acceptable oral dose can provide a detectable in vitro effect, 4) comprise fewer than four or preferably no amide bonds, and 5) capable of inhibiting leukocyte chemotaxis at nanomolar or sub-nanomolar concentrations.This invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds in treating a variety of inflammatory and immune system disorders. Additionally, this invention relates to the use such compounds as probes for the localization of C5a receptors.

67. 发明申请

US20070208017A1 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors 有权
标题翻译：作为mPGES-1抑制剂的2-（苯基或杂环）-1H-苯并[9,10-d]咪唑
公开(公告)号：US20070208017A1
公开(公告)日：2007-09-06
申请号：US11374288
申请日：2005-11-23
申请人： Anh Chau , Bernard Cote , Yves Ducharme , Richard Frenette , Richard Friesen , Marc Gagnon , Andre Giroux , Evelyn Martins , Hongping Yu , Tom Wu
发明人： Anh Chau , Bernard Cote , Yves Ducharme , Richard Frenette , Richard Friesen , Marc Gagnon , Andre Giroux , Evelyn Martins , Hongping Yu , Tom Wu
IPC分类号： A61K31/5377 , A61K31/4439 , A61K31/4245 , A61K31/4188 , C07D403/14 , C07D413/14
CPC分类号： C07D235/02 , C07D235/18 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/06 , C07D405/06 , C07D413/04 , C07D413/06
摘要： The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.
摘要翻译：本发明包括式I的新化合物或其药学上可接受的盐。这些化合物是微粒体前列腺素E合酶-1（mPGES-1）酶的抑制剂，因此可用于治疗各种疾病或病症如骨关节炎，类风湿性关节炎和急性或慢性疼痛的疼痛和/或炎症。还包括治疗由mPGES-1酶和药物组合物介导的疾病或病症的方法。

68. 发明申请

US20070167634A1 METHOD FOR PREPARING IRBESARTAN AND INTERMEDIATES THEREOF 有权
标题翻译：制备IRBESARTAN及其中间体的方法
公开(公告)号：US20070167634A1
公开(公告)日：2007-07-19
申请号：US11688635
申请日：2007-03-20
申请人： Edgar Miranda , Cornelis Vlaar , Jingyang Zhu
发明人： Edgar Miranda , Cornelis Vlaar , Jingyang Zhu
IPC分类号： C07D487/10
CPC分类号： C07D235/02 , C07D403/10
摘要： A method for preparing irbesartan and intermediates thereof. Irbesartan has the structure of formula I,
摘要翻译：厄贝沙坦及其中间体的制备方法。厄贝沙坦具有式I的结构，

69. 发明申请

US20070112033A1 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions 审中-公开
标题翻译： β-激动剂，其制备方法及其作为药物组合物的用途
公开(公告)号：US20070112033A1
公开(公告)日：2007-05-17
申请号：US11550827
申请日：2006-10-19
申请人： Thomas Trieselmann , Rainer Walter , Matthew Netherton , Marco Santagostino , Bradford Hamilton
发明人： Thomas Trieselmann , Rainer Walter , Matthew Netherton , Marco Santagostino , Bradford Hamilton
IPC分类号： C07D403/02 , A61K31/4439 , A61K31/4184
CPC分类号： C07D235/02 , C07D235/06 , C07D235/26
摘要： The present invention relates to new beta-agonists of general formula (I) wherein the groups R1 to R4 have the meanings given in ths claims and specification, the tautomers, racemates, enantiomers, diastereomers, solvates, hydrates, mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, methods of preparing these compounds and their use as pharmaceutical compositions.
摘要翻译：本发明涉及通式（I）的新的β-激动剂，其中基团R 1至R 4具有权利要求和说明书中给出的含义，互变异构体，其外消旋物，对映异构体，非对映异构体，溶剂合物，水合物，其混合物，其前药及其盐，特别是其与无机或有机酸或碱的生理上可接受的盐，制备这些化合物的方法及其作为药物组合物的用途。

70. 发明申请

US20060292073A1 Stereoselective Synthesis of Amino Acid Analogs for Tumor Imaging 审中-公开
标题翻译：用于肿瘤成像的氨基酸类似物的立体选择性合成
公开(公告)号：US20060292073A1
公开(公告)日：2006-12-28
申请号：US11425051
申请日：2006-06-19
申请人： Mark Goodman , Weiping Yu
发明人： Mark Goodman , Weiping Yu
IPC分类号： A61K51/00 , C07F13/00 , C07D345/00 , C07C61/04
CPC分类号： C07D235/02 , A61K51/04 , A61K51/0402 , C07C61/04 , C07C227/20 , C07C233/81 , C07C233/84 , C07C271/24 , C07C303/28 , C07C2601/04 , C07C2601/14 , C07C309/73 , C07C229/48 , C07C309/65
摘要： The radiolabeled non-natural amino acid 1-amino-3-cyclobutane-1-carboxylic acid (ACBC) and its analogs are candidate tumor imaging agents useful for positron emission tomography and single photon emission computed tomography due to their selective affinity for tumor cells. The present invention provides methods for stereo-selective synthesis of syn-ACBC analogs. The disclosed synthetic strategy is reliable and efficient and can be used to synthesize a gram quantity of various syn-isomers of the ACBC analogs, particularly, syn-[18F]-1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC) and syn-[123I]-1-amino-3-iodocyclobutane-1-carboxylic (IACBC) acid analogs.
摘要翻译：放射性标记的非天然氨基酸1-氨基-3-环丁烷-1-羧酸（ACBC）及其类似物是用于正电子发射断层扫描和单光子发射计算机断层摄影的候选肿瘤成像剂，由于它们对肿瘤细胞的选择性亲和力。本发明提供了立体选择性合成syn-ACBC类似物的方法。所公开的合成策略是可靠和有效的，并且可以用于合成一定数量的ACBC类似物，特别是顺式 - [F 18 F] -1-氨基-3-氟环丁烷的各种顺式异构体 -1-羧酸（FACBC）和顺式 - [123 I] -1-氨基-3-碘代环丁烷-1-羧酸（IACBC）酸类似物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式